Assembling the evidence…
BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of cutaneous or subcutaneous edema. There is clinical need for treatments that reduce the rate of HAE attacks in patients. OBJECTIVES: Primary objectives were to evaluate the effectiveness of lanadelumab on attack-free rate (AFR; proportion of patients who had zero HAE attacks), and of every 2-week and every 4-week adjustments on AFR. METHODS: A retrospective medical chart review study was conducted in 19 HAE centers and included data from patients with type I or II HAE treated with lanadelumab (index treatment) in Germany, France, Greece, and Austria who were aged 12 years or older (ClinicalTrials.gov identifier: NCT04861090). Data abstraction occurred September 15, 2021, to June 29, 2022. Analyses were primarily descriptive. RESULTS: Data from 198 patients were collected (61.6% female, 91.9% with type I HAE). Lanadelumab treatment patterns varied between countries. Cumulative AFR improved from 0% (preindex) to 54.4% (12 months postindex) and 39.4% (postindex; median duration, 28.8 months). Monthly AFRs varied from 16.2% to 28.3% preindex (17.7% AFR in the month before index date), and from 82.7% (month 1) to more than 95% at multiple time points between 26 and 43 months postindex. Patients with interval increases (n = 144 [72.7%]) showed improved cumulative AFR (0% preindex to 50.0% postindex). CONCLUSIONS: This real-world study demonstrates that lanadelumab long-term prophylaxis is effective in improving AFR in patients with type I/II HAE on every 2-week dosing and dose interval increases. Effectiveness with lanadelumab is rapid and was observed starting from the first month of starting therapy.
This real-world study demonstrates that lanadelumab long-term prophylaxis is effective in improving AFR in patients with type I/II HAE on every 2-week dosing and dose interval increases.
causal effectiveness is not identified by the uncontrolled historical pre-post comparison
Effectiveness with lanadelumab is rapid and was observed starting from the first month of starting therapy.
month-one improvement is descriptive and lacks a concurrent comparator for causal attribution
Cumulative AFR improved from 0% (preindex) to 54.4% (12 months postindex) and 39.4% (postindex; median duration, 28.8 months).
the direction is reported consistently, but eligibility guaranteed a non-attack-free preindex period
Patients with interval increases (n = 144 [72.7%]) showed improved cumulative AFR (0% preindex to 50.0% postindex).
interval extension was selected for patients already doing well and was not modeled comparatively
Derived from the full evaluation — not a separate score.
Strengths
The cohort covers 198 patients at 19 centers in Germany, France, Austria, and Greece, providing a broader practice sample than the cited single-center studies.
↳ Methods, Study design; Results, Site characteristics
The study reports the frequency, timing, reasons, and subsequent reversal of dosing-interval increases, including that 82.6% were extended because patients were stably attack-free.
↳ Results, Lanadelumab dosing interval increase
The paper defines AFR calculations, observation windows, interval groupings, and date imputation, and explicitly states that the interval-change analysis did not model treatment-selection decisions.
↳ Methods, Statistical analysis; Discussion, limitations
Limitations
The primary analysis compares preindex and postindex periods without a concurrent control or sensitivity analysis for regression to the mean, secular change, or natural attack variability.
↳ Methods, Study design and Statistical analysis; Table III
Most extensions occurred after patients were already stably attack-free, and the paper acknowledges that extended and Q2W groups differed. The analysis does not model those differences before concluding that effectiveness was maintained.
↳ Results, Lanadelumab dosing interval increase; Discussion, pp. 386–387
The Abstract and Conclusions state that the study demonstrates rapid effectiveness, although the historical pre-post design supports an observed association rather than an identified treatment effect.
↳ Abstract, Conclusions; Discussion, final paragraph
The study’s principal addition is its description of lanadelumab interval adjustments across 19 European centers, including reasons for increasing and later decreasing intervals. The primary AFR analysis remains an uncontrolled historical comparison, and eligibility required at least one preindex attack, leaving regression to the mean and natural fluctuation unresolved. Table IV and the Discussion show that interval increases were commonly selected after patients became stably attack-free, yet no multivariable or comparative model addressed that selection. Clear reporting and engagement with HELP and HELP OLE support the descriptive value of the work, but the Abstract and Conclusions frame the findings more causally than the design permits.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Limited2.5
Confidence mediumThe study meaningfully extends prior work by documenting dosing-interval changes and attack patterns across 19 European centers, although the core effectiveness result largely confirms established trial evidence. The contribution is therefore useful but incremental.
“A total of 144 (72.7%) patients had evidence of at least 1 increase in lanadelumab dosing interval during follow-up.”
The cohort, windows, outcomes, and descriptive analyses are clearly defined, but the uncontrolled pre-post comparison does not address regression to the mean or temporal confounding. Requiring a preindex attack and then using causal-effectiveness language materially undermines identification of the headline effect.
“The analysis of patients with interval changes was descriptive and did not attempt to model the interval change decision.”
The manuscript is well organized and its tables and figures make the descriptive outcomes easy to follow. Its Abstract and Conclusions nevertheless say the study “demonstrates” effectiveness, which is stronger than an uncontrolled historical comparison supports.
“This real-world study demonstrates that lanadelumab long-term prophylaxis is effective in improving AFR.”
The Discussion compares the findings with HELP, HELP OLE, and smaller interval-extension studies and acknowledges chart and modeling limitations. It omits regression to the mean for the overall comparison and maintains an effectiveness conclusion after acknowledging systematic differences in interval-change groups.
“Patients who stayed on an increased interval were likely different from those who remained on Q2W.”
Caveats4 of 4 checks
The principal counts and AFR percentages are internally consistent, but the duration attached to the entire-postindex AFR differs between the Abstract/Results and Table III. The discrepancy is minor and does not reverse the reported outcome pattern.
Ethics arrangements, registration, sponsorship, medical-writing support, and conflicts are disclosed. Sponsor employees participated in the paper and sponsor-funded personnel contributed to analysis, operations, and writing, making the disclosed involvement material to interpretation.
Flags: 3 declared / 5 total
16 of 16 checkable references verified
18 references in manuscript 2 are books, websites or datasets — counted, but not index-checkable
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
The study observes prescribing and interval adjustment in routine practice across 19 centers, placing the evidence in an operational setting. Readiness is limited because interval changes were selected by physicians and were not modeled comparatively.
“The analysis of patients with interval changes was descriptive.”
AI-generated, human-governed. Something look off? Contact us to request a review.